Evolution of Acquired Resistance to Anti-cancer Therapy

Overview

Journal J Theor Biol

Publisher Elsevier

Specialty Biology

Date 2014 Apr 1

PMID 24681298

Citations 115

Authors

Jasmine Foo

Franziska Michor

Affiliations

Soon will be listed here.

Abstract

Acquired drug resistance is a major limitation for the successful treatment of cancer. Resistance can emerge due to a variety of reasons including host environmental factors as well as genetic or epigenetic alterations in the cancer cells. Evolutionary theory has contributed to the understanding of the dynamics of resistance mutations in a cancer cell population, the risk of resistance pre-existing before the initiation of therapy, the composition of drug cocktails necessary to prevent the emergence of resistance, and optimum drug administration schedules for patient populations at risk of evolving acquired resistance. Here we review recent advances towards elucidating the evolutionary dynamics of acquired drug resistance and outline how evolutionary thinking can contribute to outstanding questions in the field.

Citing Articles

TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.

Calistri N, Liby T, Hu Z, Zhang H, Dane M, Gross S Sci Rep. 2025; 15(1):4294.

PMID: 39905117 PMC: 11794704. DOI: 10.1038/s41598-024-82218-9.

Multilevel Mechanisms of Cancer Drug Resistance.

Roszkowska M Int J Mol Sci. 2024; 25(22).

PMID: 39596466 PMC: 11594576. DOI: 10.3390/ijms252212402.

High-density sampling reveals volume growth in human tumours.

Angaji A, Owusu M, Velling C, Dick N, Weghorn D, Berg J Elife. 2024; 13.

PMID: 39587846 PMC: 11594531. DOI: 10.7554/eLife.95338.

Exploring Genetic Silencing: RNAi and CRISPR-Cas Potential against Drug Resistance in Malaria.

Gaona-Lopez C, Rivera G Mini Rev Med Chem. 2024; 25(2):128-137.

PMID: 38932611 DOI: 10.2174/0113895575306957240610102626.

TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.

Calistri N, Liby T, Hu Z, Zhang H, Dane M, Gross S bioRxiv. 2024; .

PMID: 38895265 PMC: 11185620. DOI: 10.1101/2024.06.04.596911.

References

Sarkar S, Ma W, Sandri G . On fluctuation analysis: a new, simple and efficient method for computing the expected number of mutants. Genetica. 1992; 85(2):173-9. DOI: 10.1007/BF00120324. View

Martin R, Fisher M, Minchin R, Teo K . Optimal control of tumor size used to maximize survival time when cells are resistant to chemotherapy. Math Biosci. 1992; 110(2):201-19. DOI: 10.1016/0025-5564(92)90038-x. View

Tredan O, Galmarini C, Patel K, Tannock I . Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007; 99(19):1441-54. DOI: 10.1093/jnci/djm135. View

Orr H . The distribution of fitness effects among beneficial mutations. Genetics. 2003; 163(4):1519-26. PMC: 1462510. DOI: 10.1093/genetics/163.4.1519. View

Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293(5531):876-80. DOI: 10.1126/science.1062538. View

Kim M, Gillies R, Rejniak K . Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues. Front Oncol. 2013; 3:278. PMC: 3831268. DOI: 10.3389/fonc.2013.00278. View

Burgess M, Sawyers C . Treating imatinib-resistant leukemia: the next generation targeted therapies. ScientificWorldJournal. 2006; 6:918-30. PMC: 5917346. DOI: 10.1100/tsw.2006.184. View

Togashi Y, Masago K, Fukudo M, Terada T, Ikemi Y, Kim Y . Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J Thorac Oncol. 2010; 5(5):601-5. DOI: 10.1097/JTO.0b013e3181d32287. View

Goker E, Waltham M, Kheradpour A, Trippett T, Mazumdar M, Elisseyeff Y . Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood. 1995; 86(2):677-84. View

10.

Foo J, Michor F . Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput Biol. 2009; 5(11):e1000557. PMC: 2766072. DOI: 10.1371/journal.pcbi.1000557. View

11.

Murray J, Coldman A . The effect of heterogeneity on optimal regimens in cancer chemotherapy. Math Biosci. 2003; 185(1):73-87. DOI: 10.1016/s0025-5564(03)00093-2. View

12.

Kaeda J, OShea D, Szydlo R, Olavarria E, Dazzi F, Marin D . Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood. 2006; 107(10):4171-6. PMC: 1895293. DOI: 10.1182/blood-2005-08-3320. View

13.

Synold T, Dussault I, Forman B . The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001; 7(5):584-90. DOI: 10.1038/87912. View

14.

Hsu P, Sabatini D . Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134(5):703-7. DOI: 10.1016/j.cell.2008.08.021. View

15.

Anderson A, Weaver A, Cummings P, Quaranta V . Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell. 2006; 127(5):905-15. DOI: 10.1016/j.cell.2006.09.042. View

16.

Komarova N . Stochastic modeling of drug resistance in cancer. J Theor Biol. 2005; 239(3):351-66. DOI: 10.1016/j.jtbi.2005.08.003. View

17.

El-Deiry W . Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol. 1997; 9(1):79-87. DOI: 10.1097/00001622-199701000-00013. View

18.

Kaern M, Elston T, Blake W, Collins J . Stochasticity in gene expression: from theories to phenotypes. Nat Rev Genet. 2005; 6(6):451-64. DOI: 10.1038/nrg1615. View

19.

Chmielecki J, Foo J, Oxnard G, Hutchinson K, Ohashi K, Somwar R . Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011; 3(90):90ra59. PMC: 3500629. DOI: 10.1126/scitranslmed.3002356. View

20.

Goodman L, Wintrobe M . Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc. 2010; 132:126-32. DOI: 10.1001/jama.1946.02870380008004. View